Clinical trials: Systemic Treatment
Sepsis, Severe Sepsis
Piperacillin PK Analysis in Severe Sepsis Patients
Antibiotic dosing in septic patients poses a challenge for clinicians due to the pharmacokinetic changes seen in this population.
- Trial name
- NCT02569086
- Testing
- Blood draw
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- University of Aarhus
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Churg Strauss Syndrome
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent…
- Trial name
- MATOCSS (NCT00527566)
- Testing
- Mepolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
Systemic Sclerosis, Shortness of Breath
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis.
- Conditions
- Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
- Trial name
- NCT01051960
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
- Trial name
- NCT01492088
- Testing
- Brentuximab vedotin
- Where
- 18 sites in United States, France and 6 more
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.